Associated Papers
Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants.
Nguyen-Hoang N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider.
Roncato R et al.
British Journal of Clinical Pharmacology, 2026
Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy.
Baraka B et al.
Medical Sciences (basel, Switzerland), 2026
Optimizing fluoropyrimidine therapy: Real-world impact of DPYD genotype-based dosing on severe toxicity rates.
van Kan AHE et al.
British Journal of Clinical Pharmacology, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Development of a comprehensive cardiovascular disease genetic risk assessment test.
Amendola LM et al.
Genetics in Medicine Open, 2026
Addressing genetic diversity and health inequities: RELIVAF's proposal for Latin American pharmacogenomic guidelines.
Quiñones LA et al.
Frontiers in Pharmacology, 2026
A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.
Boige V et al.
Journal of the National Cancer Institute, 2025
Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity.
Cui E et al.
Cancer Chemotherapy and Pharmacology, 2025
Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer.
Brooks GA et al.
Cancer Chemotherapy and Pharmacology, 2025
Germline mutational landscape in a large cohort of Indian breast cancer.
Peter J et al.
Bmc Cancer, 2025
Clinical implementation and outcome evaluation of dihydropyrimidine dehydrogenase (DPYD) pharmacogenomic testing for fluoropyrimidine dosing in a Canadian Provincial Healthcare center.
Wu F et al.
Clinical Biochemistry, 2025
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.
Peeters SLJ et al.
International Journal of Cancer, 2025
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - A secondary analysis of the PREPARE trial.
De Mattia E et al.
Oncogene, 2025
Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil.
Phannasil P et al.
Biomedical Reports, 2025
Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study.
Goel V et al.
Jco Global Oncology, 2025
Risk vs Prevalence: Weighing Routine DPYD Variant Testing Prior to Fluoropyrimidine-Based Chemotherapy.
Larkey NE et al.
Clinical Chemistry, 2025
Opportunities and Challenges of Population Pharmacogenomics.
Zhou Y et al.
Annals of Human Genetics, 2025
Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant.
Thet PN et al.
Bmj Case Reports, 2025
A Lack of Complete Linkage Disequilibrium Between c.1236G>A and c.1129-5923C>G HapB3 Variants of DPYD: A Call to Revise European Pharmacogenetic Guidelines.
Gil-Rodriguez A et al.
International Journal of Molecular Sciences, 2025
A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity.
Helsby N et al.
Cancer Chemotherapy and Pharmacology, 2025
Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
Bernsen EC et al.
Clinical Pharmacology and Therapeutics, 2025
Unrecognized mutations in DPYD* 2 A wild-type rectal cancer patients receiving postoperative 5-FU-based chemotherapy - do they have a clinical impact?
Liersch P et al.
Cancer Chemotherapy and Pharmacology, 2025
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial.
Glewis S et al.
British Journal of Clinical Pharmacology, 2025
The Path to Clinical Implementation of <italic>DPYD</italic> Pharmacogenetic Testing: Long-Term Experience from an External Quality Assessment Provider and a University Testing Center.
Hedtke M et al.
Oncology Research and Treatment, 2025
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Knikman JE et al.
European Journal of Cancer (oxford, England : 1990), 2025
Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.
Díaz-Villamarín X et al.
Journal of Personalized Medicine, 2025
Impact of Upfront DPYD Genotyping on Fluoropyrimidine Adjuvant Therapy in Colorectal Cancer: A Real-World Data.
Saarenheimo J et al.
Clinical Colorectal Cancer, 2025
Precision Treatment of Patients With GI Cancer Using Pre-emptive DPYD Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil.
Fiebrich-Westra HB et al.
Jco Precision Oncology, 2025
Cracking rare disorders: a new minimally invasive RNA-seq protocol.
De Cock L et al.
Npj Genomic Medicine, 2025
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews.
Otero-Torres S et al.
Pharmaceuticals (basel, Switzerland), 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
Ho TT et al.
Clinical Pharmacology and Therapeutics, 2025
Implementing DPYD genotyping to predict chemotherapy toxicity in Australia: a feasibility study.
White C et al.
Internal Medicine Journal, 2025
Application of dihydropyrimidine dehydrogenase deficiency testing for the prevention of fluoropyrimidine toxicity: a real-world experience in a Southern Italy cancer center.
Bianchino G et al.
Journal of Chemotherapy (florence, Italy), 2025
Differences in DPYD Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study.
Gil-Rodriguez A et al.
Pharmaceuticals (basel, Switzerland), 2025
Adjuvant treatment with Capecitabine in patients who received orthotopic liver transplantation with incidental diagnosis of intrahepatic cholangiocarcinoma. Implications on DPYD polymorphisms assessment: report of two cases and review of the literature.
Liguori C et al.
Cancer Chemotherapy and Pharmacology, 2025
Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical Implications.
Sánchez-Bayona R et al.
Cancers, 2025
Genetic and Functional Characterization of DPYD Exon 4 Deletion Common in the Finnish Population.
Kiiski JI et al.
Basic & Clinical Pharmacology & Toxicology, 2025
Large-Scale Pharmacogenomics Analysis of Patients With Cancer Within the 100,000 Genomes Project Combining Whole-Genome Sequencing and Medical Records to Inform Clinical Practice.
Leong IUS et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2025
Pharmacogenomics: DPYD and Prevention of Toxicity.
Keen J et al.
Clinical Oncology (royal College of Radiologists (great Britain)), 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing.
Shamaei Zadeh A et al.
Cancer Chemotherapy and Pharmacology, 2025
Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution.
D'Amato M et al.
World Journal of Gastrointestinal Oncology, 2025
DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.
Vilquin P et al.
Cancer Chemotherapy and Pharmacology, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia.
Gil-Rodríguez A et al.
Frontiers in Pharmacology, 2025
Unveiling the heritability of selected unexplored pharmacogenetic markers in the Saudi population.
Alshabeeb MA et al.
Frontiers in Pharmacology, 2025